ECAT FOUNDATION

External quality Control for Assays and Tests

With a focus on Thrombosis and Haemostasis

REPORT



SURVEY 2024-H3 Haemophilia Labcode 1492

Copyright © 2024 ECAT Foundation



Version:

1.0.0

Survey: 2024-H3 Page 2 of 7 28-October-2024 Labcode: 1492

Date of Issue	:	28-October-2024	
Survey	:	2024-H3	
Report	:	Haemophilia	

Note:

In the Survey Manual 2024 detailed information is given regarding the ECAT external quality assessment programme, including the statistical evaluation and explanation of the report.

This Survey Manual 2024 should be considered as an integral part of this survey report.

Please notice the information regarding the homogeneity of samples used and the between-laboratory variation in the paragraph on the statistical evaluation of the Survey Manual.

General Information

Complaints

Any complaints regarding this survey report should be reported to the ECAT before **December 12th, 2024**. Complaints received after this date will not be taken into consideration.

Exclusion of results

Results < [value] or > [value] are excluded in the statistical evaluation. When other results (e.g. deviating results) are excluded in the statistical evaluation, these results are placed between brackets.

Multiple instruments

Participants have the possibility to submit per parameter results for three different instruments and or methods. However, some participants have submitted three times the same results, suggesting that this are separate results. This is not the case and may affect the statistical evaluation. The results from the second and third test system have been excluded in the statistical evaluation.

Please, do not submit multiple times the same results anymore in future surveys.

Kovaltry and Jivi

Because of the limited number of results for both parameters: Kovaltry (Clotting/Chromogenic) and Jivi (Clotting/Chromogenic), the minimum number used for the calculation of the CV and Z-score is 5.

This report is authorized by: Dr. P. Meijer (Director)

<u>Note</u>: The actual Survey Manual can be downloaded by going to the "Participant Area" of the ECAT website, login and go to the option "View Documents".

ECAT Foundation

Director: Dr. P. Meijer ECAT Office P.O. Box 107 2250 AC Voorschoten, The Netherlands phone +31 (0) 71 3030 910; fax + 31 (0) 71 3030 919 E-mail: info@ecat.nl Website: www.ecat.nl VAT number: NL802836872B01

Registration number with the Chamber of Commerce (KvK) Gouda : 41174102 General terms of delivery are applicable to all our services.

All rights reserved. No part of this report may be reproduced, stored in a retrieval system, or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from the ECAT Foundation.



Survey: 2024-H3 Page 3 of 7 28-October-2024 1492 Labcode:

1.0.0 Version:

		OVERVIEW Z-SC	ORES						
UV:Satisfactory (-2 ≤ Z-score ≤ 2) UV: Need attention (-3 < Z-score < -2 or 2 < Z-score < UV:Unsatisfactory (Z-score ≤ -3 or ≥ 3 BV: Unacceptable									
							Bivarate		
Module	Parameter	Sample	Test System	Total	Assay	Method	Analysis		
Factor IX Inhibitor	Factor IX Inhibitor	24.176	1	-0.45	-0.37	-0.43			
		24.177	1	-0.55	-0.45	-0.45			



Factor IX Inhibitor

Survey: 2024-H3 Page 4 of 7 28-October-2024 Labcode: 1492

Factor IX Inhibitor

Version:

1.0.0


Sample No	24,176					
•		hibitor level of approx. 3.0 BU/mL				
Sample Details						
Prior Use	None					
Unit	BU/mL					
Expiry Date	30-April-2027					
Homogeneity	3.8 %	Homogeneity Parameter	FIX inhibitor			
	For any method used for the measurement of this parameter with a CV \leq 12.7% the criterion for					
	homogeneity could not be	met and the Z-scores should be interprete	d with caution. See for further details			
	the paragraph on the stati	stical evaluation in the Survey Manual.				
Number of Participants	268					
Number of Responders	254	Response Rate	95 %			
Comments	The following participar	nt reported a deviating result which was	s excluded in the statistical evaluation			
	U 1 1	used by an accidental mix-up of the sar				
	0	, , , , , , , , , , , , , , , , , , , ,				
	9907169: 15.7 BU/r	nL				


Participant **3828** submitted for three instruments the same results. The results of the second and third instrument were excluded in the statistical evaluation.

Own Reagent											
	n	assigned value	Uncert.	CV (%)	Range	your result	z-score	your result	z-score	your result	z-score
Total Group	270	3.1	0.04	16.0	0.2 - 6.7	2.9	-0.45				
Buffered Normal Pooled Plasma	184	3.1	0.05	17.1	0.2 - 6.7	2.9	-0.37				
Buffer	69	3.1	0.08	16.9	2.2 - 6.7	2.9	-0.43				

Other Reagents

	n	assigned value	Uncert.	CV (%)	Range
Total Group	270	3.1	0.04	16.0	0.2 - 6.7
Buffered Normal Pooled Plasma	184	3.1	0.05	17.1	0.2 - 6.7
Buffer + Albumin	19	3.0	0.09	10.7	2.0 - 3.4
Factor IX deficient plasma	79	3.1	0.08	17.8	0.3 - 5.5
Heat-inactivated normal plasma	8	3.0			1.7 - 4.7
Other	8	4.0			2.8 - 6.7
Unknown	1	0.2			-
Non-buffered Normal Pooled Plasma	86	3.2	0.06	13.9	2.0 - 5.0
Buffer	44	3.1	0.09	14.6	2.3 - 4.0
Buffer + Albumin	1	3.8			-
Factor IX deficient plasma	26	3.1	0.08	10.2	2.6 - 3.7
Heat-inactivated normal plasma	4	3.4			3.3 - 5.0
Other	10	3.3	0.27	20.5	2.6 - 4.2
Unknown	1	2.0			-





Buffer



Factor IX Inh

Sample No Sample Details Prior Use Unit Expiry Date Survey: 2024-H3 Page 5 of 7 28-October-2024 Labcode: 1492

hibitor		Factor IX Inhibitor
	24.177	
	Plasma with a Factor IX Inhibitor level of	approx. 13 BU/mL
	None	
	BU/mL	
	30-April-2027	

3.1 % FIX inhibitor Homogeneity Homogeneity Parameter For any method used for the measurement of this parameter with a CV ≤ 10.3% the criterion for homogeneity could not be met and the Z-scores should be interpreted with caution. See for further details the paragraph on the statistical evaluation in the Survey Manual. Number of Participants 268 Number of Responders 254 **Response Rate** 95 % Comments The following participant reported a deviating result which was excluded in the statistical evaluation. This result might be caused by an accidental mix-up of the sample 24.176 and 24.177: **9907169**: 3.9 BU/mL

 The following participants reported deviating results which were excluded in the statistical evaluation:

 137:
 0.0 BU/mL

 1226;
 1
 BU/mL

 9907210:
 0
 BU/mL

1.0.0

Version:

Participant **3828** submitted for three instruments the same results. The results of the second and third instrument were excluded in the statistical evaluation.

Own Reagent

	n	assigned	Uncert.	CV (%)	Range	your	z-score	your	z-score	your	z-score
		value				result		result		result	
Total Group	266	13.3	0.19	19.0	4.1 - 28.6	11.9	-0.55				
Buffered Normal Pooled Plasma	181	13.1	0.24	20.1	4.1 - 28.6	11.9	-0.45				
Buffer	67	12.9	0.34	17.4	5.8 - 23.8	11.9	-0.45				




Survey: 2024-H3 Page 6 of 7 28-October-2024


Version: 1.0.0

Labcode: 1492

Other Reagents

	n	assigned	Uncert.	CV (%)	Range
		value			
Total Group	266	13.3	0.19	19.0	4.1 - 28.6
Buffered Normal Pooled Plasma	181	13.1	0.24	20.1	4.1 - 28.6
Buffer + Albumin	19	13.1	0.65	17.2	8.6 - 16.0
Factor IX deficient plasma	79	13.2	0.40	21.8	6.3 - 26.1
Heat-inactivated normal plasma	7	12.9			6.6 - 16.3
Other	8	15.8			4.1 - 28.6
Unknown	1	7.7			-
Non-buffered Normal Pooled Plasma	85	13.7	0.30	16.4	4.9 - 27.2
Buffer	44	13.7	0.48	18.7	4.9 - 25.7
Buffer + Albumin	1	15.4			-
Factor IX deficient plasma	26	13.2	0.44	13.6	6.2 - 22.9
Heat-inactivated normal plasma	4	14.9			14.0 - 27.2
Other	9	13.0			11.2 - 20.3
Unknown	1	15.0			-







External quality Control for Assays and Tests With a focus on Thrombosis and Haemostasis Survey: 2024-H3 Page 7 of 7 28-October-2024 Labcode: 1492

Version: 1.0.0

